Quotient Sciences, the unique and innovative provider of drug development services, today announced it has received a British Private Equity & Venture Capital Association (BVCA) Management Team Award.
Quotient’s Mark Egerton receiving BVCA Award
Recognised as the outstanding business in the Large Company category, the national award was presented to Quotient’s CEO Mark Egerton, and CFO Gordon Cameron, at last night’s annual BVCA Gala Dinner at the London Hilton on Park Lane.
Now in its eighth year, the BVCA Management Team Awards are the only awards to honour and reward the achievements and success of businesses across the UK which are backed by private equity and venture capital-backed management teams.
The judges commented: “The Quotient team under Mark Egerton are building a very exciting clinical services business, recognised in their sector by customers and competitors for developing a unique Translational Pharmaceutics solution others are unable to match. We admire their courage in investing heavily in this new approach and recognise the rewards they are achieving through rapid growth.”
Bill Priestley, Chief Investment Partner at Electra Partners, and Chair of the MTA national judging panel, said: “The national winners are of an extremely high-calibre. All of them are success stories in their own right and act as a further demonstration of the impact our industry is having on the UK economy. Private equity and venture capital is all about supporting enterprise and driving innovation, and the management team of each of these businesses prove just how well this can work. Congratulations to all – a set of highly-deserving winners and each should be very proud of their achievement.”
Mark Egerton, CEO of Quotient Clinical, said: “I am very proud of everything that we have accomplished at Quotient. This award acknowledges all of the hard work and dedication of my colleagues within the company and the service they deliver to our customers. To gain recognition at a national level from the BVCA is a great achievement, and we look forward to continuing this success as the company evolves.”